KSQ-001

N/A

Report date: 2023/12/04 10:52:51

Base Information

Drug NameKSQ-001

Drug Alias NameKSQ-001EX eTILKSQ-001EXKSQ001KSQ-001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionSuppressor of cytokine signaling 1 inhibitorsT lymphocyte replacements

TargetsSuppressor of cytokine signaling 1

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesKSQ Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center KSQ Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A